# EDGAR Filing Document

**Accession Number:** 0001012477
**File Stem:** 0001104659-26-014389
**Filing Date:** 2026-2
**Character Count:** 12065
**Document Hash:** 096a67c611a63f03b7b074fc05e1513e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-014389.hdr.sgml**: 20260212

**ACCESSION NUMBER**: 0001104659-26-014389

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260212

**DATE AS OF CHANGE**: 20260212

**EFFECTIVENESS DATE**: 20260212

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVADEL PHARMACEUTICALS PLC
- **CENTRAL INDEX KEY:** 0001012477
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-213154
- **FILM NUMBER:** 26627335

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 10 EARLSFORT TERRACE
- **CITY:** DUBLIN 2
- **PROVINCE COUNTRY:** L2
- **ZIP:** D02 T380
- **BUSINESS PHONE:** 636-449-1830

**MAIL ADDRESS:**
- **STREET 1:** 16640 CHESTERFIELD GROVE ROAD
- **STREET 2:** SUITE 200
- **CITY:** CHESTERFIELD
- **STATE:** MO
- **ZIP:** 63005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLAMEL TECHNOLOGIES SA
- **DATE OF NAME CHANGE:** 19960422

**As filed with the Securities and Exchange Commission on February 12, 2026**

**Registration No. 333-177591**

**Registration No. 333-212585**

**Registration No. 333-213154**

**Registration No. 333-219016**

**Registration No. 333-252956**

**Registration No. 333-263620**

**Registration No. 333-279501**

**Registration No. 333-289369**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-177591**

**Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-212585**

**Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-213154**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-219016**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-252956**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-263620**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-279501**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-289369**

**FORM S-8 POS**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**AVADEL PHARMACEUTICALS PLC**

**(Exact name of Registrant as Specified in Its Charter)**

---

| | |
|:---|:---|
| **Ireland** | **98-1341933** |
| **(State or other jurisdiction of**<br> **Incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**10 Earlsfort Terrace**

**Dublin 2, Ireland, D02 T380**

**(Address of principal executive offices)**

**2007 Stock Option Plan**

**2010 Stock Option Plan**

**Plan for Allocation of Free Shares December 2007**

**Plan for Allocation of Free Shares April 2008**

**Plan for Allocation of Free Shares December 2008**

**Plan for Allocation of Free Shares December 2009** 

**Plan for Allocation of Free Shares December 2010**

**Issue of Warrants 2008**

**Issue of Warrants 2009**

**Issue of Warrants 2010**

**Issue of Warrants 2011**

**2012 Stock Option Plan**

**2013 Stock Option Plan**

**2014 Stock Option Plan**

**2013 Plan Allocation for Warrants**

**2014 Plan Allocation for Warrants**

**2015 Plan Allocation for Warrants**

**2012 Plan Allocation for Free Shares**

**2013 Plan Allocation for Free Shares**

**2014 Plan Allocation for Free Shares**

**2016 Free Share Plan**

**2016 Stock Option Plan**

**2016 Stock Warrant Plan**

**2017 Omnibus Incentive Compensation Plan**

**2017 Employee Share Purchase Plan**

**Avadel Pharmaceuticals plc 2020 Omnibus Incentive Compensation Plan**

**Avadel Pharmaceuticals plc 2021 Inducement Plan**

**(Full titles of the plans)**

**c/o Alkermes plc**

**David J. Gaffin, Esq.**

**Connaught House**

**1 Burlington Road**

**Dublin 4, Ireland D04 C5Y6**

**(Name and address of agent for service)**

**+353-1-772-8000**

**(Telephone number, including area code, of agent for service)**

***Copies to:***

**Chelsea N. Darnell, Esq.**

**Paul, Weiss, Rifkind, Wharton & Garrison LLP**

**1285 Avenue of the Americas**

**New York, New York 10019-6064**

**(212) 373-3000**

**Stephen FitzSimons, Esq.**

**McCann FitzGerald LLP**

**Riverside One, Sir John Rogerson's Quay**

**Dublin 2, D02 X576, Ireland**

**+353-1-829-0000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | ◻ |
| Non-accelerated filer | ◻ | Smaller reporting company | ◻ |
|  |  | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**TERMINATION OF REGISTRATION**

These Post-Effective Amendments related to the following Registration Statements on Form S-8 (collectively, the "Registration Statements") previously filed by Avadel Pharmaceuticals plc (the "Registrant" or the "Company") with the Securities and Exchange Commission (the "SEC") are being filed to deregister any and all shares of the Company's ordinary shares, nominal value $0.01 per share ("Ordinary Shares"), registered but unsold or otherwise unissued under each such Registration Statement as of the date hereof:

1. Registration File No. 333-177591, filed with the SEC on [October 28, 2011](https://www.sec.gov/Archives/edgar/data/1012477/000114420411060063/v234240_s8.htm) , as amended by that Post-Effective Amendment No. 1, filed with the SEC on [January 10, 2017](https://www.sec.gov/Archives/edgar/data/1012477/000114420417001612/v456530_s8pos.htm) , relating to the registration of 3,350,000 Ordinary Shares for issuance under the 2007 Stock Option Plan, 2010 Stock Option Plan, Plan for Allocation of Free Shares December 2007, Plan for Allocation of Free Shares April 2008, Plan for Allocation of Free Shares December 2008, Plan for Allocation of Free Shares December 2009, Plan for Allocation of Free Shares December 2010, Issue of Warrants 2008, Issue of Warrants 2009, Issue of Warrants 2010 and Issue of Warrants 2011.

2. Registration File No. 333-212585, filed with the SEC on [July 19, 2016](https://www.sec.gov/Archives/edgar/data/1012477/000114420416113570/v444239_s8.htm) , as amended by that Post-Effective Amendment No. 1, filed with the SEC on [January 10, 2017](https://www.sec.gov/Archives/edgar/data/1012477/000114420417001609/0001144204-17-001609-index.htm) , relating to the registration of 4,900,000 Ordinary Shares for issuance under the 2012 Stock Option Plan, 2013 Stock Option Plan, 2014 Stock Option Plan, 2013 Plan Allocation for Warrants, 2014 Plan Allocation for Warrants, 2015 Plan Allocation for Warrants, 2012 Plan Allocation for Free Shares, 2013 Plan Allocation for Free Shares and 2014 Plan Allocation for Free Shares.

3. Registration File No. 333-213154, filed with the SEC on [August 16, 2016](https://www.sec.gov/Archives/edgar/data/1012477/000114420416119757/0001144204-16-119757-index.htm) , as amended by that Post-Effective Amendment No. 1, filed with the SEC on [January 10, 2017](https://www.sec.gov/Archives/edgar/data/1012477/000114420417001611/v456529_s8pos.htm) , relating to the registration of 2,600,000 Ordinary Shares for issuance under the 2016 Free Share Plan, 2016 Stock Option Plan and 2016 Stock Warrant Plan.

4. Registration File No. 333-219016, filed with the SEC on [June 28, 2017](https://www.sec.gov/Archives/edgar/data/1012477/000091068017000068/0000910680-17-000068-index.htm) , relating to the registration of 4,000,000 Ordinary Shares for issuance under the 2017 Omnibus Incentive Compensation Plan and 1,000,000 Ordinary Shares for issuance under the 2017 Employee Share Purchase Plan.

5. Registration File No. 333-252956, filed with the SEC on [February 10, 2021](https://www.sec.gov/Archives/edgar/data/1012477/000110465921019878/tm215871d1_s8.htm) , relating to the registration of 6,000,000 Ordinary Shares for issuance under the 2020 Omnibus Incentive Compensation Plan.

6. Registration File No. 333-263620, filed with the SEC on [March 16, 2022](https://www.sec.gov/Archives/edgar/data/1012477/000110465922034566/tm229276d1_s8.htm) , relating to the registration of 1,500,000 Ordinary Shares for issuance under the 2021 Inducement Plan.

7. Registration File No. 333-279501, filed with the SEC on [May 17, 2024](https://www.sec.gov/Archives/edgar/data/1012477/000110465924063022/tm2413709d1_s8.htm) , relating to the registration of 6,500,000 Ordinary Shares for issuance under the 2020 Omnibus Incentive Compensation Plan.

8. Registration File No. 333-289369, filed with the
 SEC on [August 7, 2025](https://www.sec.gov/Archives/edgar/data/1012477/000110465925075214/tm2522704d1_s8.htm) , relating to the registration of 500,000 Ordinary Shares for issuance under the 2021 Inducement
 Plan.

On February 12, 2026, pursuant to the Transaction Agreement, dated October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement, dated November 18, 2025 (as amended, the "Transaction Agreement"), by and between the Company and Alkermes plc ("Alkermes"), Alkermes acquired the Company pursuant to a court-sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme"). As a result of the Scheme, the Company became a wholly owned subsidiary of Alkermes.

As a result of the consummation of the transactions contemplated by the Transaction Agreement, the Registrant has terminated all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any securities which remain unsold at the termination of the offerings, the Registrant hereby removes and withdraws from registration any and all securities of the Registrant registered pursuant to the Registration Statements that remain unsold or otherwise unissued as of the date hereof, if any. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statements.

The foregoing description of the Transaction Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Transaction Agreement, which is attached as Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the SEC on October 22, 2025, and Amendment No. 1 to the Transaction Agreement, which is attached as Exhibit 2.2 to the Company's Current Report on Form 8-K filed with the SEC on November 19, 2025.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, in the Country of Ireland, on February 12, 2026.

---

| | |
|:---|:---|
| AVADEL PHARMACEUTICALS PLC | AVADEL PHARMACEUTICALS PLC |
| By: | /s/ Declan O'Connor |
|  | Declan O'Connor <br> Director |

---

Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the specified registration statements on Form S-8.